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Abstract
Obesity has become a world-wide pandemic and is considered a major risk factor for 
various diseases. Despite this, recent intriguing clinical observations have been made 
suggesting that being overweight has some advantages. Overweight and some obese 
patients were reported to have significantly lower all-cause mortality, described as the 
‘obesity paradox’. This phenomenon resulted in increased research aimed at 
investigating the influence of adipose tissue on outcomes of various clinical states 
including critical illness. In this review, we summarise research findings on the effect 
burn injury and trauma-related critical illness have on adipose tissue and discuss 
potential mechanisms by which adipose tissue influences outcomes in burn and other 
critically ill patients. Burn injury and critical illness influence adipose tissue functionally 
and morphologically, with circulating levels of fat derived hormones, adipokines, altered 
in patients following injury and/or critical illness. As adipokines regulate a variety of 
processes including inflammation and metabolism, this disruption in the adipokine axis 
may explain the obesity paradox phenomenon observed in critically ill patients. We 
conclude that further research on the influence of individual adipokines on prognosis in 
burn and critically ill patients and the mechanisms involved is required to increase 
understanding of their therapeutic potential.
Highlights
 The Obesity Paradox has been reported in critically ill populations.
 Burn injury and critical illness affect adipose tissue morphologically and 
functionally.
 Adipokines exert anti- and pro-inflammatory effects influencing patient outcomes.
 Current scar reduction treatments utilising adipose tissue potentially mediate 
their effects through release of adipokines.
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Abbreviations
APACHE Acute Physiological Assessment and Chronic Health Evaluation
CRP C-Reactive Protein
FFA Free Fatty Acids
HMG-CoA Hydroxymethyl Glutaryl Coenzyme A
IL Interleukin
RCT Randomised Controlled Trial
SAPS Simplified Acute Physiology Score
SOFA Sequential Organ Failure Assessment
Introduction
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Obesity is a complex multifactorial condition that affects over a third of the world’s 
population [1]. With increasing prevalence of overweight and obese individuals [2, 3], 
obesity is being described as a global pandemic [4] as obesity greatly impacts the 
individual’s health status and quality of life[5, 6] being a major risk factor for various 
pathologies including cancer, cardiovascular disease, diabetes and osteoarthritis [7]. 
In this context a recent and intriguing observation is that all-cause mortality is reported 
to be significantly lower in overweight and some obese patients [8]. This phenomenon, 
where outcomes are paradoxically better in overweight and obese patients compared to 
normal weight individuals, is described as the ‘obesity paradox’ and is the subject of 
increasing interest in scientific and medical communities [9-12]. The underlying 
mechanisms behind this phenomenon remain poorly understood and this is particularly 
the case in critically ill populations where the data on the obesity paradox are limited.
This review aims to summarise the observations suggesting the presence of the obesity 
paradox in critically ill patients, including burns and to discuss potential mechanisms 
that may explain the difference in outcomes between normal weight, overweight and 
obese patients, focusing primarily on hormones secreted by adipose tissue 
(adipokines). 
Adipose Tissue in Burns and Critical Illness
Adipose tissue is one of the largest organs in the human body. Importantly, it is no 
longer deemed an inert tissue that serves the roles of thermal/mechanical insulation 
protecting internal organs from external stimuli (such as cold and shock) or as an 
energy storage modality. Since the discovery in 1994 of leptin, an adipokine or adipose-
derived hormone capable of controlling body energy balance [13], adipose tissue is now 
recognised as endocrine organ able to influence metabolism and inflammatory status. 
As a result extensive research has been carried out investigating potential roles of 
adipokines in various clinical conditions including autoimmune and inflammatory 
disorders and connective tissue diseases [14], metabolic disorders [15, 16], 
cardiovascular and neurovascular diseases [17], and cancer [18, 19].
Despite increasing interest in adipose tissues’ role in clinical pathologies, its role in the 
context of critical illness including burns and trauma remains to be fully elucidated. With 
thousands of critically ill patients admitted to intensive care units every year [20] some 
interesting observations have been made. Patients requiring prolonged critical care 
were reported to lose lean body mass while adipose tissue mass remained preserved or 
even increased [21, 22]. Furthermore, although morbid obesity (BMI ≥ 40 kg/m2) is an 
independent risk factor for mortality in critically ill patients [23], improved survival rates 
were observed among overweight (BMI 25-30 kg/m2) and obese (BMI 30-40 kg/m2) 
patients compared to normal BMI patients during critical illness [23-26]. These 
paradoxical findings have stimulated research in to the interplay between critical illness 
and adipose tissue and their influence on patient outcomes. Moreover the profound 
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inflammatory and metabolic response to burn and trauma related critical illness suggest 
a potential involvement for adipose tissue and adipokines.
Critical illness following injury is a multifactorial heterogeneous disorder characterised 
by an overwhelming pro-inflammatory response accompanied by a compensatory anti-
inflammatory reaction and subsequent immunosuppression [27, 28].This classical 
paradigm also applies to severe forms of critical illness such as burns, the pathology of 
which we have described previously [29, 30]. The human response to burn injury 
includes a so-called ‘genomic storm’[31], consistent with simultaneous increased 
systemic inflammation, innate immune activation and anti-inflammatory response [32, 
33], as well as suppression of adaptive immunity[31]. In addition, burn patients and 
others with severe critical illness suffer from a prolonged hypermetabolic, hypercatabolic 
response [33, 34].
The metabolic response following thermal injury is characterised as a two phase 
response: the ‘ebb’ phase within 48 hours where metabolism, cardiac output and 
oxygen consumption are reduced, followed by the ‘flow’ phase at approximately 120 
hours post-injury where these parameters increase and plateau [35]. This metabolic 
response includes: peripheral lipolysis and free fatty acid (FFA) [36] oxidation leading to 
an acute, global and complex increase in FFA levels[37]; systemic induction of 
endoplasmic reticulum (ER) stress and unfolded protein response [38]; up to 6-fold 
increase in breakdown rates of skeletal muscle protein[39]; elevation in resting energy 
expenditure up to 140%[40] that can be prolonged [33].
Burns and other severe critical illnesses have been reported to influence adipose tissue 
morphologically and functionally.  Saraf et al reported the impact of severe burn injury 
on subcutaneous white adipose tissue in children and observed  significantly reduced 
adipocyte size, increased collagen deposition and cell mitochondria content, increased 
immune cells such macrophages, as well as increased inflammatory cytokine 
production [41]. These morphological changes suggest “browning” of subcutaneous 
adipose tissue following thermal injury, a finding which was confirmed biochemically and 
functionally. Sidossis et al reported significantly increased mitochondrial density and 
mitochondrial respiratory capacity, as well as an 80-fold increase in the expression of 
uncoupling protein 1 (UCP1), a molecule abundantly observed in brown adipose tissue 
depots [42], in burn patients compared to healthy controls [43]. In addition, Patsouris et 
al reported similar findings including significantly increased mitochondrial mass and 
adipose tissue browning markers in burn patients [44].  This could be a compensatory 
mechanism since brown adipose tissue is known to induce thermogenesis, modulate 
energy expenditure and exert local tissue effects such as stimulating angiogenesis and 
influencing macrophage polarization [45]. Similar morphological and metabolic activity 
alterations of adipose tissue have been reported in critically ill patients[46, 47]. A 
functional aspect of adipose tissue is its endocrine role through the production of 
adipokines and these may mediate many of the effects seen in burns and critical illness.
Adipose tissue and adipokines in Critical Illness 5
Overview of Adipokines and their Biological Effects
There are approximately 600 identified hormones secreted by adipose tissue [48], 
providing a rich source of potential novel biomarkers  and therapeutic targets for the 
management of various pathologies. In this review, we will focus on Adiponectin, 
Ghrelin, Leptin, Resistin and Visfatin as the best characterised adipokines. 
Adiponectin is released exclusively from white adipose tissue[49], and is the most 
abundant adipose-specific adipokine, with expression in subcutaneous fat being greater 
than visceral fat [50]. Adiponectin has anti-inflammatory effects [51]. Ghrelin is an 
orexigenic hormone that is an endogenous ligand to growth hormone and was initially 
thought to be produced mainly by the stomach [52], but has subsequently been 
identified in other tissues including adipose tissue [53]. Ghrelin signaling is associated 
with adiposity, changes in fat distribution and mobilisation, independent of growth 
hormone and dietary intake[54, 55]. Leptin is primarily secreted by subcutaneous white 
adipose tissue, the amount of leptin secreted into the circulation is proportional to 
adipose tissue mass and nutritional status[51]. Leptin exhibits structural similarities to 
cytokines [56] and is pro-inflammatory [57]. Resistin is also a pro-inflammatory 
adipokine expressed by adipocytes and other tissues including skeletal muscle [58, 59]. 
Visfatin, also called pre-B-cell colony enhancing factor, is primarily secreted by 
adipocytes in visceral white adipose tissue and exhibits pro-inflammatory effects [60]. 
Relevant to this review, adipokines have been reported to influence skin and adipose 
tissue. Adiponectin and ghrelin have been observed to exert anti-inflammatory and anti-
fibrotic effects on skin [61-63] and were reported to enhance wound healing rates [64, 
65]. Similarly, leptin has been observed to enhance human epidermal keratinocyte and 
epithelial cell proliferation, differentiation and migration, as well as promote 
angiogenesis within dermal connective tissues [66]. However, leptin was also found to 
be overexpressed in hypertrophic and keloid scars [67]. This could be due to increased 
pro-inflammatory cytokine release associated with leptin, as seen in inflammatory skin 
conditions [68]. Visfatin has been reported to enhance chemokine and antimicrobial 
peptide production in human keratinocytes [69, 70], as well as exhibit anti-fibrotic 
properties[71].
Adiponectin and leptin have been reported to induce browning of adipose tissue [72, 73] 
and adiponectin promotes adipogenesis as well as increasing lipid accumulation and 
insulin responsiveness of adipocytes [74]. In contrast, leptin inhibits insulin-dependent 
glucose uptake and lipogenesis and reverses insulin-induced lipolysis [75]. Ghrelin 
stimulates adipogenesis and glucose uptake, as well as inhibiting lipolysis, apoptosis 
and autophagy of adipocytes [76, 77]. Resistin and visfatin enhance pro-inflammatory 
cytokine expression in adipose tissue including TNF-α and IL-6 [78, 79]. Similarly, 
resistin and visfatin induce insulin resistance in adipocytes [79, 80]. The influence of 
these adipokines is not limited to skin and adipose tissue. The beneficial and 
detrimental effects of these adipokines on various cell types and tissues are 
summarized in Figure 1 and the reader is also referred to recent reviews for further 
detail [17, 81-88].
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Figure 1. Effects of adipokines on various tissues and organs
Adipokine changes in burns and critically ill patients 
Several studies have demonstrated acute reductions in circulating adiponectin levels in 
critical illness and/or injury including burns, sepsis and trauma [89-95]. In addition, an 
inverse association was reported between serum adiponectin levels and severity of 
illness as measured by C-Reactive Protein (CRP), Simplified Acute Physiology Score 
(SAPS) II and Sequential Organ Failure Assessment (SOFA) scores [91, 92, 95]. 
Similar findings were observed in patients with acute pancreatitis, where adiponectin 
levels in the blood were negatively associated with severity of disease and incidence of 
tissue necrosis [93]. Furthermore, adiponectin levels progressively increase with patient 
recovery [91, 94]. Although the above findings indicate that decreased serum 
adiponectin levels may lead to poor outcomes, other research has reported different 
findings. Circulating adiponectin levels in severely ill patients did not correlate with 
inflammatory markers including Interleukin (IL) -6, IL-10 and Tumour Necrosis Factor 
(TNF)-α [89, 96, 97] and clinical scores including Acute Physiologic Assessment and 
Chronic Health Evaluation (APACHE) II score and SOFA [96, 98, 99]. Furthermore, 
higher blood adiponectin levels were associated with increased risk of mortality during 
critical illness[100-103].
Only two studies have investigated circulating ghrelin levels in critical illness. Wade et al 
reported significantly reduced ghrelin levels in severely burned patients correlating with 
metabolic/caloric needs.  No other associations with other parameters such as injury 
severity and inflammatory status were observed [89]. Santacruz et al also observed 
significantly reduced plasma ghrelin levels in critically ill patients but saw no correlations 
with feeding status [104].
Leptin levels in the blood have been reported to be elevated in critical illness [105-108]. 
Furthermore, leptin was positively associated with pro-inflammatory status of severely ill 
patients, as measured by CRP, IL-6, sTNFR1 and TNF-α [106, 108-111]. Additionally, 
other studies have reported that serum-soluble leptin receptor (SLR) in patients 
correlated with inflammatory response and illness severity as measured by IL-6, lactate, 
procalcitonin and APACHE II score [112, 113]. Interestingly, elevated levels of leptin 
were observed in survivors of acute sepsis [105], while increased SLR levels in critically 
ill patients were associated with increased mortality [112]. However, other studies have 
reported different findings. Blood leptin levels in severely ill patients were similar or 
reduced compared to healthy volunteers [89, 94, 95, 109, 112, 114] and no associations 
were found between circulating leptin levels and inflammatory status, illness severity, or 
mortality in critical illness [94, 95, 107, 109, 111, 112, 114]. 
In contrast to the heterogeneity of results reported on the impact adiponectin, ghrelin 
and leptin on critical illness outcomes, the influence of resistin and visfatin on outcomes 
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of severely ill patients is consistent in the literature. Critically ill patients exhibit 
significantly elevated circulating levels of resistin [89, 95, 98, 99, 111, 115-120] and 
visfatin [111, 121-127]. Additionally, both resistin and visfatin significantly correlated 
with pro-inflammatory responses (including CRP, IL-6, IL-8  and TNF-α), and worse 
clinical severity scores (including APACHE II, Glasgow Coma score, multiple organ 
dysfunction score, SAPS II and SOFA)[89, 95, 98, 99, 111, 115-119, 121-127]. 
Furthermore, high resistin and visfatin levels in blood were associated with poor 
outcomes including mortality [116, 117, 122-126].
A systematic review examining the evidence for adipokines having an influence on 
critical care patients has been published recently [128]. It concludes that although 
strong observations were reported indicating the influence of adipokines on the 
prognosis of critical illness, additional larger studies that incorporate more diverse 
cohorts (such as age, gender, BMI, ethnic groups and different pathologies) is required 
to better understand the relationship between adipokines and critical illness. This is 
essential in order to validate the potential clinical value and utility of adipokines as 
diagnostic and/or prognostic biomarkers, as well their potential as therapeutic targets in 
critical illness including burn and trauma. Furthermore, studies to date have investigated 
the association of adipokines with critical illness in the acute setting only. This focus on 
the acute setting has further limited the translation of adipokines in clinical settings. 
Importantly, since medical care advancements have improved survival rates after critical 
trauma [129-131], greater emphasis is now placed on the  prevention and treatment of 
potentially debilitating long-term sequelae experienced by survivors of severe illness 
including chronic critical illness [132-134], prolonged pathophysiological responses[33] 
and scarring [135]. 
Conclusions
Several studies have reported changes in the serum levels of specific adipokines and 
their role in the regulation of a range of biological responses to injury including 
inflammation, metabolic dysregulation and wound healing is emerging. However a 
robust characterisation of the impact of such changes in individual adipokines on patient 
outcomes, especially in burns patients, is lacking. Large clinical and scientific studies 
are required to establish the mechanisms by which adipose tissue may influence patient 
outcomes and translate the research into clinical practice to improve short and long-
term outcomes of burn and critically ill patients.
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Highlights
 The Obesity Paradox has been reported in critically ill populations.
 Burn injury and critical illness affect adipose tissue morphologically and 
functionally.
 Adipokines exert anti- and pro-inflammatory effects influencing patient 
outcomes.
 Current validated medical treatments utilize adipose tissue and potentially 
adipokines.
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Abstract
Obesity has become a world-wide pandemic and is considered a major risk factor for 
various diseases. Despite this, recent intriguing clinical observations have been made 
suggesting that being overweight has some advantages. Overweight and some obese 
patients were reported to have significantly lower all-cause mortality, described as the 
‘obesity paradox’. This phenomenon resulted in increased research aimed at 
investigating the influence of adipose tissue on outcomes of various clinical states 
including critical illness. In this review, we summarise research findings on the effect 
burn injury and trauma-related critical illness have on adipose tissue and discuss 
potential mechanisms by which adipose tissue influences outcomes in burn and other 
critically ill patients. Burn injury and critical illness influence adipose tissue functionally 
and morphologically, with circulating levels of fat derived hormones, adipokines, altered 
in patients following injury and/or critical illness. As adipokines regulate a variety of 
processes including inflammation and metabolism, this disruption in the adipokine axis 
may explain the obesity paradox phenomenon observed in critically ill patients. We 
conclude that further research on the influence of individual adipokines on prognosis in 
burn and critically ill patients and the mechanisms involved is required to increase 
understanding of their therapeutic potential.
Highlights
 The Obesity Paradox has been reported in critically ill populations.
 Burn injury and critical illness affect adipose tissue morphologically and 
functionally.
 Adipokines exert anti- and pro-inflammatory effects influencing patient outcomes.
 Current scar reduction treatments utilising adipose tissue potentially mediate 
their effects through release of adipokines.
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Introduction
Adipose tissue and adipokines in Critical Illness 3
Obesity is a complex multifactorial condition that affects over a third of the world’s 
population [1]. With increasing prevalence of overweight and obese individuals [2, 3], 
obesity is being described as a global pandemic [4] as obesity greatly impacts the 
individual’s health status and quality of life[5, 6] being a major risk factor for various 
pathologies including cancer, cardiovascular disease, diabetes and osteoarthritis [7]. 
In this context a recent and intriguing observation is that all-cause mortality is reported 
to be significantly lower in overweight and some obese patients [8]. This phenomenon, 
where outcomes are paradoxically better in overweight and obese patients compared to 
normal weight individuals, is described as the ‘obesity paradox’ and is the subject of 
increasing interest in scientific and medical communities [9-12]. The underlying 
mechanisms behind this phenomenon remain poorly understood and this is particularly 
the case in critically ill populations where the data on the obesity paradox are limited.
This review aims to summarise the observations suggesting the presence of the obesity 
paradox in critically ill patients, including burns and to discuss potential mechanisms 
that may explain the difference in outcomes between normal weight, overweight and 
obese patients, focusing primarily on hormones secreted by adipose tissue 
(adipokines). 
Adipose Tissue in Burns and Critical Illness
Adipose tissue is one of the largest organs in the human body. Importantly, it is no 
longer deemed an inert tissue that serves the roles of thermal/mechanical insulation 
protecting internal organs from external stimuli (such as cold and shock) or as an 
energy storage modality. Since the discovery in 1994 of leptin, an adipokine or adipose-
derived hormone capable of controlling body energy balance [13], adipose tissue is now 
recognised as endocrine organ able to influence metabolism and inflammatory status. 
As a result extensive research has been carried out investigating potential roles of 
adipokines in various clinical conditions including autoimmune and inflammatory 
disorders and connective tissue diseases [14], metabolic disorders [15, 16], 
cardiovascular and neurovascular diseases [17], and cancer [18, 19].
Despite increasing interest in adipose tissues’ role in clinical pathologies, its role in the 
context of critical illness including burns and trauma remains to be fully elucidated. With 
thousands of critically ill patients admitted to intensive care units every year [20] some 
interesting observations have been made. Patients requiring prolonged critical care 
were reported to lose lean body mass while adipose tissue mass remained preserved or 
even increased [21, 22]. Furthermore, although morbid obesity (BMI ≥ 40 kg/m2) is an 
independent risk factor for mortality in critically ill patients [23], improved survival rates 
were observed among overweight (BMI 25-30 kg/m2) and obese (BMI 30-40 kg/m2) 
patients compared to normal BMI patients during critical illness [23-26]. These 
paradoxical findings have stimulated research in to the interplay between critical illness 
and adipose tissue and their influence on patient outcomes. Moreover the profound 
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inflammatory and metabolic response to burn and trauma related critical illness suggest 
a potential involvement for adipose tissue and adipokines.
Critical illness following injury is a multifactorial heterogeneous disorder characterised 
by an overwhelming pro-inflammatory response accompanied by a compensatory anti-
inflammatory reaction and subsequent immunosuppression [27, 28].This classical 
paradigm also applies to severe forms of critical illness such as burns, the pathology of 
which we have described previously [29, 30]. The human response to burn injury 
includes a so-called ‘genomic storm’[31], consistent with simultaneous increased 
systemic inflammation, innate immune activation and anti-inflammatory response [32, 
33], as well as suppression of adaptive immunity[31]. In addition, burn patients and 
others with severe critical illness suffer from a prolonged hypermetabolic, hypercatabolic 
response [33, 34].
The metabolic response following thermal injury is characterised as a two phase 
response: the ‘ebb’ phase within 48 hours where metabolism, cardiac output and 
oxygen consumption are reduced, followed by the ‘flow’ phase at approximately 120 
hours post-injury where these parameters increase and plateau [35]. This metabolic 
response includes: peripheral lipolysis and free fatty acid (FFA) [36] oxidation leading to 
an acute, global and complex increase in FFA levels[37]; systemic induction of 
endoplasmic reticulum (ER) stress and unfolded protein response [38]; up to 6-fold 
increase in breakdown rates of skeletal muscle protein[39]; elevation in resting energy 
expenditure up to 140%[40] that can be prolonged [33].
Burns and other severe critical illnesses have been reported to influence adipose tissue 
morphologically and functionally.  Saraf et al reported the impact of severe burn injury 
on subcutaneous white adipose tissue in children and observed  significantly reduced 
adipocyte size, increased collagen deposition and cell mitochondria content, increased 
immune cells such macrophages, as well as increased inflammatory cytokine 
production [41]. These morphological changes suggest “browning” of subcutaneous 
adipose tissue following thermal injury, a finding which was confirmed biochemically and 
functionally. Sidossis et al reported significantly increased mitochondrial density and 
mitochondrial respiratory capacity, as well as an 80-fold increase in the expression of 
uncoupling protein 1 (UCP1), a molecule abundantly observed in brown adipose tissue 
depots [42], in burn patients compared to healthy controls [43]. In addition, Patsouris et 
al reported similar findings including significantly increased mitochondrial mass and 
adipose tissue browning markers in burn patients [44].  This could be a compensatory 
mechanism since brown adipose tissue is known to induce thermogenesis, modulate 
energy expenditure and exert local tissue effects such as stimulating angiogenesis and 
influencing macrophage polarization [45]. Similar morphological and metabolic activity 
alterations of adipose tissue have been reported in critically ill patients[46, 47]. A 
functional aspect of adipose tissue is its endocrine role through the production of 
adipokines and these may mediate many of the effects seen in burns and critical illness.
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Overview of Adipokines and their Biological Effects
There are approximately 600 identified hormones secreted by adipose tissue [48], 
providing a rich source of potential novel biomarkers  and therapeutic targets for the 
management of various pathologies. In this review, we will focus on Adiponectin, 
Ghrelin, Leptin, Resistin and Visfatin as the best characterised adipokines. 
Adiponectin is released exclusively from white adipose tissue[49], and is the most 
abundant adipose-specific adipokine, with expression in subcutaneous fat being greater 
than visceral fat [50]. Adiponectin has anti-inflammatory effects [51]. Ghrelin is an 
orexigenic hormone that is an endogenous ligand to growth hormone and was initially 
thought to be produced mainly by the stomach [52], but has subsequently been 
identified in other tissues including adipose tissue [53]. Ghrelin signaling is associated 
with adiposity, changes in fat distribution and mobilisation, independent of growth 
hormone and dietary intake[54, 55]. Leptin is primarily secreted by subcutaneous white 
adipose tissue, the amount of leptin secreted into the circulation is proportional to 
adipose tissue mass and nutritional status[51]. Leptin exhibits structural similarities to 
cytokines [56] and is pro-inflammatory [57]. Resistin is also a pro-inflammatory 
adipokine expressed by adipocytes and other tissues including skeletal muscle [58, 59]. 
Visfatin, also called pre-B-cell colony enhancing factor, is primarily secreted by 
adipocytes in visceral white adipose tissue and exhibits pro-inflammatory effects [60]. 
Relevant to this review, adipokines have been reported to influence skin and adipose 
tissue. Adiponectin and ghrelin have been observed to exert anti-inflammatory and anti-
fibrotic effects on skin [61-63] and were reported to enhance wound healing rates [64, 
65]. Similarly, leptin has been observed to enhance human epidermal keratinocyte and 
epithelial cell proliferation, differentiation and migration, as well as promote 
angiogenesis within dermal connective tissues [66]. However, leptin was also found to 
be overexpressed in hypertrophic and keloid scars [67]. This could be due to increased 
pro-inflammatory cytokine release associated with leptin, as seen in inflammatory skin 
conditions [68]. Visfatin has been reported to enhance chemokine and antimicrobial 
peptide production in human keratinocytes [69, 70], as well as exhibit anti-fibrotic 
properties[71].
Adiponectin and leptin have been reported to induce browning of adipose tissue [72, 73] 
and adiponectin promotes adipogenesis as well as increasing lipid accumulation and 
insulin responsiveness of adipocytes [74]. In contrast, leptin inhibits insulin-dependent 
glucose uptake and lipogenesis and reverses insulin-induced lipolysis [75]. Ghrelin 
stimulates adipogenesis and glucose uptake, as well as inhibiting lipolysis, apoptosis 
and autophagy of adipocytes [76, 77]. Resistin and visfatin enhance pro-inflammatory 
cytokine expression in adipose tissue including TNF-α and IL-6 [78, 79]. Similarly, 
resistin and visfatin induce insulin resistance in adipocytes [79, 80]. The influence of 
these adipokines is not limited to skin and adipose tissue. The beneficial and 
detrimental effects of these adipokines on various cell types and tissues are 
summarized in Figure 1 and the reader is also referred to recent reviews for further 
detail [17, 81-88].
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Figure 1. Effects of adipokines on various tissues and organs
Adipokine changes in burns and critically ill patients 
Several studies have demonstrated acute reductions in circulating adiponectin levels in 
critical illness and/or injury including burns, sepsis and trauma [89-95]. In addition, an 
inverse association was reported between serum adiponectin levels and severity of 
illness as measured by C-Reactive Protein (CRP), Simplified Acute Physiology Score 
(SAPS) II and Sequential Organ Failure Assessment (SOFA) scores [91, 92, 95]. 
Similar findings were observed in patients with acute pancreatitis, where adiponectin 
levels in the blood were negatively associated with severity of disease and incidence of 
tissue necrosis [93]. Furthermore, adiponectin levels progressively increase with patient 
recovery [91, 94]. Although the above findings indicate that decreased serum 
adiponectin levels may lead to poor outcomes, other research has reported different 
findings. Circulating adiponectin levels in severely ill patients did not correlate with 
inflammatory markers including Interleukin (IL) -6, IL-10 and Tumour Necrosis Factor 
(TNF)-α [89, 96, 97] and clinical scores including Acute Physiologic Assessment and 
Chronic Health Evaluation (APACHE) II score and SOFA [96, 98, 99]. Furthermore, 
higher blood adiponectin levels were associated with increased risk of mortality during 
critical illness[100-103].
Only two studies have investigated circulating ghrelin levels in critical illness. Wade et al 
reported significantly reduced ghrelin levels in severely burned patients correlating with 
metabolic/caloric needs.  No other associations with other parameters such as injury 
severity and inflammatory status were observed [89]. Santacruz et al also observed 
significantly reduced plasma ghrelin levels in critically ill patients but saw no correlations 
with feeding status [104].
Leptin levels in the blood have been reported to be elevated in critical illness [105-108]. 
Furthermore, leptin was positively associated with pro-inflammatory status of severely ill 
patients, as measured by CRP, IL-6, sTNFR1 and TNF-α [106, 108-111]. Additionally, 
other studies have reported that serum-soluble leptin receptor (SLR) in patients 
correlated with inflammatory response and illness severity as measured by IL-6, lactate, 
procalcitonin and APACHE II score [112, 113]. Interestingly, elevated levels of leptin 
were observed in survivors of acute sepsis [105], while increased SLR levels in critically 
ill patients were associated with increased mortality [112]. However, other studies have 
reported different findings. Blood leptin levels in severely ill patients were similar or 
reduced compared to healthy volunteers [89, 94, 95, 109, 112, 114] and no associations 
were found between circulating leptin levels and inflammatory status, illness severity, or 
mortality in critical illness [94, 95, 107, 109, 111, 112, 114]. 
In contrast to the heterogeneity of results reported on the impact adiponectin, ghrelin 
and leptin on critical illness outcomes, the influence of resistin and visfatin on outcomes 
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of severely ill patients is consistent in the literature. Critically ill patients exhibit 
significantly elevated circulating levels of resistin [89, 95, 98, 99, 111, 115-120] and 
visfatin [111, 121-127]. Additionally, both resistin and visfatin significantly correlated 
with pro-inflammatory responses (including CRP, IL-6, IL-8  and TNF-α), and worse 
clinical severity scores (including APACHE II, Glasgow Coma score, multiple organ 
dysfunction score, SAPS II and SOFA)[89, 95, 98, 99, 111, 115-119, 121-127]. 
Furthermore, high resistin and visfatin levels in blood were associated with poor 
outcomes including mortality [116, 117, 122-126].
A systematic review examining the evidence for adipokines having an influence on 
critical care patients has been published recently [128]. It concludes that although 
strong observations were reported indicating the influence of adipokines on the 
prognosis of critical illness, additional larger studies that incorporate more diverse 
cohorts (such as age, gender, BMI, ethnic groups and different pathologies) is required 
to better understand the relationship between adipokines and critical illness. This is 
essential in order to validate the potential clinical value and utility of adipokines as 
diagnostic and/or prognostic biomarkers, as well their potential as therapeutic targets in 
critical illness including burn and trauma. Furthermore, studies to date have investigated 
the association of adipokines with critical illness in the acute setting only. This focus on 
the acute setting has further limited the translation of adipokines in clinical settings. 
Importantly, since medical care advancements have improved survival rates after critical 
trauma [129-131], greater emphasis is now placed on the  prevention and treatment of 
potentially debilitating long-term sequelae experienced by survivors of severe illness 
including chronic critical illness [132-134], prolonged pathophysiological responses[33] 
and scarring [135]. 
Conclusions
Several studies have reported changes in the serum levels of specific adipokines and 
their role in the regulation of a range of biological responses to injury including 
inflammation, metabolic dysregulation and wound healing is emerging. However a 
robust characterisation of the impact of such changes in individual adipokines on patient 
outcomes, especially in burns patients, is lacking. Large clinical and scientific studies 
are required to establish the mechanisms by which adipose tissue may influence patient 
outcomes and translate the research into clinical practice to improve short and long-
term outcomes of burn and critically ill patients.
Funding
KAT is supported by a scholarship from the Kuwaiti Ministry of Health and Civil Service 
Commission, SWJ is supported by Arthritis Research UK, NM is supported by the Scar 
Free Foundation, and JML is supported by the NIHR Surgical Reconstruction and 
Microbiology Research Centre.
Adipose tissue and adipokines in Critical Illness 8
References
[1] Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, 
regional, and national prevalence of overweight and obesity in children and adults 
during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. 
Lancet. 2014;384:766-81.
[2] Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled 
analysis of 1698 population-based measurement studies with 19.2 million participants. 
Lancet. 2016;387:1377-96.
[3] Worldwide trends in body-mass index, underweight, overweight, and obesity from 
1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 
128.9 million children, adolescents, and adults. Lancet. 2017;390:2627-42.
[4] Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The 
global obesity pandemic: shaped by global drivers and local environments. Lancet. 
2011;378:804-14.
[5] Visscher TL, Seidell JC. The public health impact of obesity. Annual review of public 
health. 2001;22:355-75.
[6] Taylor VH, Forhan M, Vigod SN, McIntyre RS, Morrison KM. The impact of obesity 
on quality of life. Best practice & research Clinical endocrinology & metabolism. 
2013;27:139-46.
[7] Seidell JC, Halberstadt J. The global burden of obesity and the challenges of 
prevention. Annals of nutrition & metabolism. 2015;66 Suppl 2:7-12.
[8] Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with 
overweight and obesity using standard body mass index categories: a systematic 
review and meta-analysis. Jama. 2013;309:71-82.
[9] Braun N, Gomes F, Schutz P. "The obesity paradox" in disease--is the protective 
effect of obesity true? Swiss medical weekly. 2015;145:w14265.
[10] Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, Gillen D, et al. Obesity 
paradox in end-stage kidney disease patients. Progress in cardiovascular diseases. 
2014;56:415-25.
[11] Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular 
diseases: implications regarding fitness, fatness, and severity in the obesity paradox. 
Journal of the American College of Cardiology. 2014;63:1345-54.
[12] Valentijn TM, Galal W, Tjeertes EK, Hoeks SE, Verhagen HJ, Stolker RJ. The 
obesity paradox in the surgical population. The surgeon : journal of the Royal Colleges 
of Surgeons of Edinburgh and Ireland. 2013;11:169-76.
[13] Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional 
cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-32.
[14] Fietta P, Delsante G. Focus on adipokines. Theoretical biology forum. 
2013;106:103-29.
[15] Jialal I, Devaraj S. Subcutaneous adipose tissue biology in metabolic syndrome. 
Hormone molecular biology and clinical investigation. 2018;33.
[16] Nicholson T, Church C, Baker DJ, Jones SW. The role of adipokines in skeletal 
muscle inflammation and insulin sensitivity. Journal of inflammation (London, England). 
2018;15:9.
Adipose tissue and adipokines in Critical Illness 9
[17] Opatrilova R, Caprnda M, Kubatka P, Valentova V, Uramova S, Nosal V, et al. 
Adipokines in neurovascular diseases. Biomedicine & pharmacotherapy = Biomedecine 
& pharmacotherapie. 2018;98:424-32.
[18] Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a Matter of Fat: The 
Crosstalk between Adipose Tissue and Tumors. Trends in cancer. 2018;4:374-84.
[19] Morris EV, Edwards CM. Adipokines, adiposity, and bone marrow adipocytes: 
Dangerous accomplices in multiple myeloma. J Cell Physiol. 2018.
[20] Mullins PM, Goyal M, Pines JM. National growth in intensive care unit admissions 
from emergency departments in the United States from 2002 to 2009. Academic 
emergency medicine : official journal of the Society for Academic Emergency Medicine. 
2013;20:479-86.
[21] Hart DW, Wolf SE, Herndon DN, Chinkes DL, Lal SO, Obeng MK, et al. Energy 
expenditure and caloric balance after burn: increased feeding leads to fat rather than 
lean mass accretion. Ann Surg. 2002;235:152-61.
[22] Plank LD, Connolly AB, Hill GL. Sequential changes in the metabolic response in 
severely septic patients during the first 23 days after the onset of peritonitis. Ann Surg. 
1998;228:146-58.
[23] Nasraway SA, Jr., Albert M, Donnelly AM, Ruthazer R, Shikora SA, Saltzman E. 
Morbid obesity is an independent determinant of death among surgical critically ill 
patients. Crit Care Med. 2006;34:964-70; quiz 71.
[24] Fonarow GC, Srikanthan P, Costanzo MR, Cintron GB, Lopatin M. An obesity 
paradox in acute heart failure: analysis of body mass index and inhospital mortality for 
108,927 patients in the Acute Decompensated Heart Failure National Registry. 
American heart journal. 2007;153:74-81.
[25] Peake SL, Moran JL, Ghelani DR, Lloyd AJ, Walker MJ. The effect of obesity on 
12-month survival following admission to intensive care: a prospective study. Crit Care 
Med. 2006;34:2929-39.
[26] Trivedi V, Jean RE, Genese F, Fuhrmann KA, Saini AK, Mangulabnan VD, et al. 
Impact of Obesity on Outcomes in a Multiethnic Cohort of Medical Intensive Care Unit 
Patients. Journal of intensive care medicine. 2018;33:97-103.
[27] Greathouse KC, Hall MW. Critical Illness-Induced Immune Suppression: Current 
State of the Science. American journal of critical care : an official publication, American 
Association of Critical-Care Nurses. 2016;25:85-92.
[28] Vanzant EL, Lopez CM, Ozrazgat-Baslanti T, Ungaro R, Davis R, Cuenca AG, et al. 
Persistent inflammation, immunosuppression, and catabolism syndrome after severe 
blunt trauma. The journal of trauma and acute care surgery. 2014;76:21-9; discussion 9-
30.
[29] Al-Tarrah K, Hewison M, Moiemen N, Lord JM. Vitamin D status and its influence 
on outcomes following major burn injury and critical illness. Burns & trauma. 2018;6:11.
[30] Al-Tarrah K, Moiemen N, Lord JM. The influence of sex steroid hormones on the 
response to trauma and burn injury. Burns & trauma. 2017;5:29.
[31] Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al. A genomic 
storm in critically injured humans. J Exp Med. 2011;208:2581-90.
[32] Hampson P, Dinsdale RJ, Wearn CM, Bamford AL, Bishop JRB, Hazeldine J, et al. 
Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early 
Adipose tissue and adipokines in Critical Illness 10
Biomarkers of Sepsis in Burn-injured Patients: A Prospective Observational Cohort 
Study. Ann Surg. 2017;265:1241-9.
[33] Jeschke MG, Gauglitz GG, Kulp GA, Finnerty CC, Williams FN, Kraft R, et al. Long-
term persistance of the pathophysiologic response to severe burn injury. PloS one. 
2011;6:e21245.
[34] De Cosmi V, Milani GP, Mazzocchi A, D'Oria V, Silano M, Calderini E, et al. The 
Metabolic Response to Stress and Infection in Critically Ill Children: The Opportunity of 
an Individualized Approach. Nutrients. 2017;9.
[35] Wolfe RR. Review: acute versus chronic response to burn injury. Circ Shock. 
1981;8:105-15.
[36] Otterbein LR, Cosio C, Graceffa P, Dominguez R. Crystal structures of the vitamin 
D-binding protein and its complex with actin: structural basis of the actin-scavenger 
system. Proc Natl Acad Sci U S A. 2002;99:8003-8.
[37] Qi P, Abdullahi A, Stanojcic M, Patsouris D, Jeschke MG. Lipidomic analysis 
enables prediction of clinical outcomes in burn patients. Scientific reports. 
2016;6:38707.
[38] Jeschke MG, Finnerty CC, Herndon DN, Song J, Boehning D, Tompkins RG, et al. 
Severe Injury Is Associated With Insulin Resistance, Endoplasmic Reticulum Stress 
Response, and Unfolded Protein Response. Ann Surg. 2012;255:370-8.
[39] Chao T, Herndon DN, Porter C, Chondronikola M, Chaidemenou A, Abdelrahman 
DR, et al. Skeletal Muscle Protein Breakdown Remains Elevated in Pediatric Burn 
Survivors up to One-Year Post-Injury. Shock. 2015;44:397-401.
[40] Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, Norbury WB, et al. 
Pathophysiologic response to severe burn injury. Ann Surg. 2008;248:387-401.
[41] Saraf MK, Herndon DN, Porter C, Toliver-Kinsky T, Radhakrishnan R, Chao T, et 
al. Morphological Changes in Subcutaneous White Adipose Tissue After Severe Burn 
Injury. Journal of burn care & research : official publication of the American Burn 
Association. 2016;37:e96-103.
[42] Kalinovich AV, de Jong JM, Cannon B, Nedergaard J. UCP1 in adipose tissues: 
two steps to full browning. Biochimie. 2017;134:127-37.
[43] Sidossis LS, Porter C, Saraf MK, Borsheim E, Radhakrishnan RS, Chao T, et al. 
Browning of Subcutaneous White Adipose Tissue in Humans after Severe Adrenergic 
Stress. Cell metabolism. 2015;22:219-27.
[44] Patsouris D. Burn Induces Browning of the Subcutaneous White Adipose Tissue in 
Mice and Humans. 2015;13:1538-44.
[45] Wang GX, Zhao XY, Lin JD. The brown fat secretome: metabolic functions beyond 
thermogenesis. Trends in endocrinology and metabolism: TEM. 2015;26:231-7.
[46] Langouche L, Perre SV, Thiessen S, Gunst J, Hermans G, D'Hoore A, et al. 
Alterations in adipose tissue during critical illness: An adaptive and protective 
response? American journal of respiratory and critical care medicine. 2010;182:507-16.
[47] Marques MB, Langouche L. Endocrine, metabolic, and morphologic alterations of 
adipose tissue during critical illness. Crit Care Med. 2013;41:317-25.
[48] Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of 
biomarkers for metabolic disorders. Proteomics Clinical applications. 2012;6:91-101.
Adipose tissue and adipokines in Critical Illness 11
[49] Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein 
similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746-9.
[50] Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the 
Release of Adipokines by Adipose Tissue, Adipose Tissue Matrix, and Adipocytes from 
Visceral and Subcutaneous Abdominal Adipose Tissues of Obese Humans. 
Endocrinology. 2004;145:2273-82.
[51] Ahima RS. Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity 
(Silver Spring, Md). 2006;14 Suppl 1:9s-15s.
[52] Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a 
growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-60.
[53] Baatar D, Patel K, Taub DD. The effects of ghrelin on inflammation and the immune 
system. Molecular and cellular endocrinology. 2011;340:44-58.
[54] Sangiao-Alvarellos S, Vazquez MJ, Varela L, Nogueiras R, Saha AK, Cordido F, et 
al. Central ghrelin regulates peripheral lipid metabolism in a growth hormone-
independent fashion. Endocrinology. 2009;150:4562-74.
[55] Al Massadi O, Lopez M, Tschop M, Dieguez C, Nogueiras R. Current 
Understanding of the Hypothalamic Ghrelin Pathways Inducing Appetite and Adiposity. 
Trends in neurosciences. 2017;40:167-80.
[56] Leal VdO, Mafra D. Adipokines in obesity. Clinica Chimica Acta. 2013;419:87-94.
[57] Fernandez-Riejos P, Najib S, Santos-Alvarez J, Martin-Romero C, Perez-Perez A, 
Gonzalez-Yanes C, et al. Role of leptin in the activation of immune cells. Mediators of 
inflammation. 2010;2010:568343.
[58] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The 
hormone resistin links obesity to diabetes. Nature. 2001;409:307-12.
[59] Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and 
therapeutic considerations for cardiovascular disease. British Journal of Pharmacology. 
2012;165:622-32.
[60] Sun Z, Lei H, Zhang Z. Pre-B cell colony enhancing factor (PBEF), a cytokine with 
multiple physiological functions. Cytokine & growth factor reviews. 2013;24:433-42.
[61] Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML, et al. Levels of 
adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic 
sclerosis: potential utility as biomarker? Arthritis research & therapy. 2012;14:R102.
[62] Shibata S, Tada Y, Hau CS, Mitsui A, Kamata M, Asano Y, et al. Adiponectin 
regulates psoriasiform skin inflammation by suppressing IL-17 production from 
gammadelta-T cells. Nature communications. 2015;6:7687.
[63] Koca SS, Ozgen M, Sarikaya M, Dagli F, Ustundag B, Isik A. Ghrelin prevents the 
development of dermal fibrosis in bleomycin-induced scleroderma. Clinical and 
experimental dermatology. 2014;39:176-81.
[64] Liu C, Huang J, Li H, Yang Z, Zeng Y, Liu J, et al. Ghrelin accelerates wound 
healing through GHS-R1a-mediated MAPK-NF-κB/GR signaling pathways in combined 
radiation and burn injury in rats. Scientific reports. 2016;6.
[65] Shibata S, Tada Y, Asano Y, Hau CS, Kato T, Saeki H, et al. Adiponectin regulates 
cutaneous wound healing by promoting keratinocyte proliferation and migration via the 
ERK signaling pathway. J Immunol. 2012;189:3231-41.
Adipose tissue and adipokines in Critical Illness 12
[66] Tadokoro S, Ide S, Tokuyama R, Umeki H, Tatehara S, Kataoka S, et al. Leptin 
Promotes Wound Healing in the Skin. PloS one. 2015;10.
[67] Seleit I, Bakry OA, Samaka RM, Tawfik AS. Immunohistochemical Evaluation of 
Leptin Expression in Wound Healing: A Clue to Exuberant Scar Formation. Applied 
immunohistochemistry & molecular morphology : AIMM. 2016;24:296-306.
[68] Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson 
SI, et al. Obesity in psoriasis: Leptin and resistin as mediators of cutaneous 
inflammation. The British journal of dermatology. 2008;159:342-50.
[69] Hau CS, Kanda N, Noda S, Tatsuta A, Kamata M, Shibata S, et al. Visfatin 
enhances the production of cathelicidin antimicrobial peptide, human beta-defensin-2, 
human beta-defensin-3, and S100A7 in human keratinocytes and their orthologs in 
murine imiquimod-induced psoriatic skin. Am J Pathol. 2013;182:1705-17.
[70] Kanda N, Hau CS, Tada Y, Tatsuta A, Sato S, Watanabe S. Visfatin enhances 
CXCL8, CXCL10, and CCL20 production in human keratinocytes. Endocrinology. 
2011;152:3155-64.
[71] Masui Y, Asano Y, Shibata S, Noda S, Akamata K, Aozasa N, et al. A possible 
contribution of visfatin to the resolution of skin sclerosis in patients with diffuse 
cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and 
Th1 polarization of the immune response. Rheumatology (Oxford, England). 
2013;52:1239-44.
[72] Hui X, Gu P, Zhang J, Nie T, Pan Y, Wu D, et al. Adiponectin Enhances Cold-
Induced Browning of Subcutaneous Adipose Tissue via Promoting M2 Macrophage 
Proliferation. Cell metabolism. 2015;22:279-90.
[73] Dodd G, Descherf S, Loh K, Simonds SE, Wiede F, Balland E, et al. Leptin and 
insulin act on POMC neurons to promote the browning of white fat. Cell. 2015;160:88-
104.
[74] Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, 
insulin sensitivity, and lipid accumulation. Journal of lipid research. 2005;46:1369-79.
[75] Harris RB. Direct and indirect effects of leptin on adipocyte metabolism. Biochim 
Biophys Acta. 2014;1842:414-23.
[76] Rodriguez A. Novel molecular aspects of ghrelin and leptin in the control of 
adipobiology and the cardiovascular system. Obesity facts. 2014;7:82-95.
[77] Rodriguez A, Gomez-Ambrosi J, Catalan V, Rotellar F, Valenti V, Silva C, et al. The 
ghrelin O-acyltransferase-ghrelin system reduces TNF-alpha-induced apoptosis and 
autophagy in human visceral adipocytes. Diabetologia. 2012;55:3038-50.
[78] Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory 
cascade leading to hyperresistinemia in humans. PLoS medicine. 2004;1:e45.
[79] Chang YC, Chang TJ, Lee WJ, Chuang LM. The relationship of visfatin/pre-B-cell 
colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with 
inflammation, insulin resistance, and plasma lipids. Metabolism: clinical and 
experimental. 2010;59:93-9.
[80] Fu Y, Luo L, Luo N, Garvey WT. Proinflammatory cytokine production and insulin 
sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes. Nutrition & 
metabolism. 2006;3:28.
Adipose tissue and adipokines in Critical Illness 13
[81] Shibata R, Ouchi N, Ohashi K, Murohara T. The role of adipokines in 
cardiovascular disease. Journal of cardiology. 2017;70:329-34.
[82] Romacho T, Elsen M, Rohrborn D, Eckel J. Adipose tissue and its role in organ 
crosstalk. Acta physiologica (Oxford, England). 2014;210:733-53.
[83] Li F, Li Y, Duan Y, Hu CA, Tang Y, Yin Y. Myokines and adipokines: Involvement in 
the crosstalk between skeletal muscle and adipose tissue. Cytokine & growth factor 
reviews. 2017;33:73-82.
[84] Zhu Q, Scherer PE. Immunologic and endocrine functions of adipose tissue: 
implications for kidney disease. Nature reviews Nephrology. 2018;14:105-20.
[85] Feakins RM. Obesity and metabolic syndrome: pathological effects on the 
gastrointestinal tract. Histopathology. 2016;68:630-40.
[86] Hawkes CP, Mostoufi-Moab S. Fat-bone interaction within the bone marrow milieu: 
Impact on hematopoiesis and systemic energy metabolism. Bone. 2018.
[87] Francisco V, Perez T, Pino J, Lopez V, Franco E, Alonso A, et al. Biomechanics, 
obesity, and osteoarthritis. The role of adipokines: When the levee breaks. Journal of 
orthopaedic research : official publication of the Orthopaedic Research Society. 
2018;36:594-604.
[88] Maurizi G, Della Guardia L, Maurizi A, Poloni A. Adipocytes properties and 
crosstalk with immune system in obesity-related inflammation. J Cell Physiol. 
2018;233:88-97.
[89] Wade CE, Mora AG, Shields BA, Pidcoke HF, Baer LA, Chung KK, et al. Signals 
from fat after injury: plasma adipokines and ghrelin concentrations in the severely 
burned. Cytokine. 2013;61:78-83.
[90] Jernas M, Olsson B, Sjoholm K, Sjogren A, Rudemo M, Nellgard B, et al. Changes 
in adipose tissue gene expression and plasma levels of adipokines and acute-phase 
proteins in patients with critical illness. Metabolism: clinical and experimental. 
2009;58:102-8.
[91] Welters ID, Bing C, Ding C, Leuwer M, Hall AM. Circulating anti-inflammatory 
adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are 
inhibited in early sepsis, but increase with clinical recovery: a pilot study. BMC 
anesthesiology. 2014;14.
[92] Venkatesh B, Hickman I, Nisbet J, Cohen J, Prins J. Changes in serum adiponectin 
concentrations in critical illness: a preliminary investigation. Critical care (London, 
England). 2009;13:R105.
[93] Sharma A, Muddana V, Lamb J, Greer J, Papachristou GI, Whitcomb DC. Low 
serum adiponectin levels are associated with systemic organ failure in acute 
pancreatitis. Pancreas. 2009;38:907-12.
[94] Langouche L, Vander Perre S, Frystyk J, Flyvbjerg A, Hansen TK, Van den Berghe 
G. Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of 
pulmonary origin. Critical care (London, England). 2009;13:R112.
[95] Hillenbrand A, Knippschild U, Weiss M, Schrezenmeier H, Henne-Bruns D, Huber-
Lang M, et al. Sepsis induced changes of adipokines and cytokines - septic patients 
compared to morbidly obese patients. BMC surgery. 2010;10:26.
Adipose tissue and adipokines in Critical Illness 14
[96] Robinson K, Jones M, Ordonez J, Grice J, Davidson B, Prins J, et al. Random 
measurements of adiponectin and IL-6 may not be indicative of the 24-h profile in 
critically ill patients. Clinical endocrinology. 2013;79:892-8.
[97] Koch A, Sanson E, Voigt S, Helm A, Trautwein C, Tacke F. Serum adiponectin 
upon admission to the intensive care unit may predict mortality in critically ill patients. 
Journal of critical care. 2011;26:166-74.
[98] Yu P, Wang S, Qiu Z, Bai B, Zhao Z, Hao Y, et al. Efficacy of resistin and leptin in 
predicting persistent organ failure in patients with acute pancreatitis. Pancreatology : 
official journal of the International Association of Pancreatology (IAP)  [et al]. 
2016;16:952-7.
[99] Vassiliadi DA, Tzanela M, Kotanidou A, Orfanos SE, Nikitas N, Armaganidis A, et 
al. Serial changes in adiponectin and resistin in critically ill patients with sepsis: 
associations with sepsis phase, severity, and circulating cytokine levels. Journal of 
critical care. 2012;27:400-9.
[100] Karampela I, Kandri E, Antonakos G, Vogiatzakis E, Christodoulatos GS, 
Nikolaidou A, et al. Kinetics of circulating fetuin-A may predict mortality independently 
from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill 
patients with sepsis: A prospective study. Journal of critical care. 2017;41:78-85.
[101] Walkey AJ, Rice TW, Konter J, Ouchi N, Shibata R, Walsh K, et al. Plasma 
adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit Care 
Med. 2010;38:2329-34.
[102] Walkey AJ, Demissie S, Shah D, Romero F, Puklin L, Summer RS. Plasma 
Adiponectin, clinical factors, and patient outcomes during the acute respiratory distress 
syndrome. PloS one. 2014;9:e108561.
[103] Palakshappa JA, Anderson BJ, Reilly JP, Shashaty MG, Ueno R, Wu Q, et al. Low 
Plasma Levels of Adiponectin Do Not Explain Acute Respiratory Distress Syndrome 
Risk: a Prospective Cohort Study of Patients with Severe Sepsis. Critical care (London, 
England). 2016;20:71.
[104] Santacruz CA, Quintairos A, Righy C, Crippa IA, Couto L, Jr., Imbault V, et al. Is 
There a Role for Enterohormones in the Gastroparesis of Critically Ill Patients? Crit 
Care Med. 2017;45:1696-701.
[105] Bornstein SR, Licinio J, Tauchnitz R, Engelmann L, Negrao AB, Gold P, et al. 
Plasma leptin levels are increased in survivors of acute sepsis: associated loss of 
diurnal rhythm, in cortisol and leptin secretion. The Journal of clinical endocrinology and 
metabolism. 1998;83:280-3.
[106] Arnalich F, Lopez J, Codoceo R, Jim nez M, Madero R, Montiel C. Relationship of 
plasma leptin to plasma cytokines and human survivalin sepsis and septic shock. J 
Infect Dis. 1999;180:908-11.
[107] Tzanela M, Orfanos SE, Tsirantonaki M, Kotanidou A, Sotiropoulou C, 
Christophoraki M, et al. Leptin alterations in the course of sepsis in humans. In vivo 
(Athens, Greece). 2006;20:565-70.
[108] Kythreotis P, Kokkini A, Avgeropoulou S, Hadjioannou A, Anastasakou E, 
Rasidakis A, et al. Plasma leptin and insulin-like growth factor I levels during acute 
exacerbations of chronic obstructive pulmonary disease. BMC pulmonary medicine. 
2009;9:11.
Adipose tissue and adipokines in Critical Illness 15
[109] Papathanassoglou ED, Moynihan JA, Ackerman MH, Mantzoros CS. Serum leptin 
levels are higher but are not independently associated with severity or mortality in the 
multiple organ dysfunction/systemic inflammatory response syndrome: a matched case 
control and a longitudinal study. Clinical endocrinology. 2001;54:225-33.
[110] Yousef AA, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring 
and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective 
observational study. Critical care (London, England). 2010;14:R33.
[111] Schaffler A, Landfried K, Volk M, Furst A, Buchler C, Scholmerich J, et al. 
Potential of adipocytokines in predicting peripancreatic necrosis and severity in acute 
pancreatitis: pilot study. Journal of gastroenterology and hepatology. 2007;22:326-34.
[112] Koch A, Weiskirchen R, Zimmermann HW, Sanson E, Trautwein C, Tacke F. 
Relevance of serum leptin and leptin-receptor concentrations in critically ill patients. 
Mediators of inflammation. 2010;2010.
[113] Shapiro NI, Khankin EV, Van Meurs M, Shih SC, Lu S, Yano M, et al. Leptin 
exacerbates sepsis-mediated morbidity and mortality. J Immunol. 2010;185:517-24.
[114] Quasim T, McMillan DC, Wallace AM, Kinsella J. The relationship between leptin 
concentrations, the systemic inflammatory response and illness severity in surgical 
patients admitted to ITU. Clinical nutrition (Edinburgh, Scotland). 2004;23:233-8.
[115] Sunden-Cullberg J, Nystrom T, Lee ML, Mullins GE, Tokics L, Andersson J, et al. 
Pronounced elevation of resistin correlates with severity of disease in severe sepsis and 
septic shock. Crit Care Med. 2007;35:1536-42.
[116] Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C. Serum resistin levels in 
critically ill patients are associated with inflammation, organ dysfunction and metabolism 
and may predict survival of non-septic patients. Critical care (London, England). 
2009;13:R95.
[117] Dong XQ, Yang SB, Zhu FL, Lv QW, Zhang GH, Huang HB. Resistin is associated 
with mortality in patients with traumatic brain injury. Critical care (London, England). 
2010;14:R190.
[118] Macdonald SP, Stone SF, Neil CL, van Eeden PE, Fatovich DM, Arendts G, et al. 
Sustained elevation of resistin, NGAL and IL-8 are associated with severe sepsis/septic 
shock in the emergency department. PloS one. 2014;9:e110678.
[119] Schaffler A, Hamer O, Dickopf J, Goetz A, Landfried K, Voelk M, et al. Admission 
resistin levels predict peripancreatic necrosis and clinical severity in acute pancreatitis. 
The American journal of gastroenterology. 2010;105:2474-84.
[120] Duffy SL, Lagrone L, Herndon DN, Mileski WJ. Resistin and postburn insulin 
dysfunction. J Trauma. 2009;66:250-4.
[121] Lu LF, Yang SS, Wang CP, Hung WC, Yu TH, Chiu CA, et al. Elevated 
visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. 
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke 
Association. 2009;18:354-9.
[122] Lee KA, Gong MN. Pre-B-cell colony-enhancing factor and its clinical correlates 
with acute lung injury and sepsis. Chest. 2011;140:382-90.
[123] Chen J, Weng J-F, Hong W-C, Luo L-F, Yu W, Luo S-D. Change in plasma 
visfatin level after severe traumatic brain injury. Peptides. 2012;38:8-12.
Adipose tissue and adipokines in Critical Illness 16
[124] Yin CG, Jiang L, Tang B, Zhang H, Qian Q, Niu GZ. Prognostic significance of 
plasma visfatin levels in patients with ischemic stroke. Peptides. 2013;42:101-4.
[125] Huang Q, Dai WM, Jie YQ, Yu GF, Fan XF, Wu A. High concentrations of visfatin 
in the peripheral blood of patients with acute basal ganglia hemorrhage are associated 
with poor outcome. Peptides. 2013;39:55-8.
[126] Lee K, Huh JW, Lim CM, Koh Y, Hong SB. Clinical role of serum pre-B cell colony-
enhancing factor in ventilated patients with sepsis and acute respiratory distress 
syndrome. Scandinavian journal of infectious diseases. 2013;45:760-5.
[127] Schaffler A, Hamer OW, Dickopf J, Goetz A, Landfried K, Voelk M, et al. 
Admission visfatin levels predict pancreatic and peripancreatic necrosis in acute 
pancreatitis and correlate with clinical severity. The American journal of 
gastroenterology. 2011;106:957-67.
[128] Hajri T, Gharib M, Kaul S, Karpeh MS, Jr. Association between adipokines and 
critical illness outcomes. The journal of trauma and acute care surgery. 2017;83:507-19.
[129] Jackson PC, Hardwicke J, Bamford A, Nightingale P, Wilson Y, Papini R, et al. 
Revised estimates of mortality from the Birmingham Burn Centre, 2001-2010: a 
continuing analysis over 65 years. Ann Surg. 2014;259:979-84.
[130] Wearn C, Hardwicke J, Kitsios A, Siddons V, Nightingale P, Moiemen N. 
Outcomes of burns in the elderly: revised estimates from the Birmingham Burn Centre. 
Burns. 2015;41:1161-8.
[131] Zimmerman JE, Kramer AA, Knaus WA. Changes in hospital mortality for United 
States intensive care unit admissions from 1988 to 2012. Critical care (London, 
England). 2013;17:R81.
[132] Loss SH, Nunes DSL, Franzosi OS, Salazar GS, Teixeira C, Vieira SRR. Chronic 
critical illness: are we saving patients or creating victims? Revista Brasileira de Terapia 
Intensiva. 2017;29:87-95.
[133] Kahn JM, Le T, Angus DC, Cox CE, Hough CL, White DB, et al. The epidemiology 
of chronic critical illness in the United States*. Crit Care Med. 2015;43:282-7.
[134] Marchioni A, Fantini R, Antenora F, Clini E, Fabbri L. Chronic critical illness: the 
price of survival. European journal of clinical investigation. 2015;45:1341-9.
[135] Lee KC, Dretzke J, Grover L, Logan A, Moiemen N. A systematic review of 
objective burn scar measurements. Burns & trauma. 2016;4:14.

Funding: 
KAT is supported by a scholarship from the Kuwaiti Ministry of Health and Civil Service 
Commission, SWJ is supported by Arthritis Research UK, NM is supported by the Scar Free 
Foundation, and JML is supported by the NIHR Surgical Reconstruction and Microbiology 
Research Centre
Declaration of interest
Declarations of interest: none.
